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ated genes in IMACs as compared to i.v. MACs and mono-
cytes. By quantitative PCR, up to tenfold higher mRNA ex-
pression of 10 exemplary genes of the UPS (UBE2A, UBE2D2, 
UBE2L6, USP14, UBB and ATPase2,   2,   5,   2i/MECL-1,   5i/
LMP7) was demonstrated in i.v. MACs as compared to IMACs. 
Immunohistochemistry and Western blots confirmed these 
findings in intestinal mucosa of controls and patients suffer-
ing from diverticulitis. In contrast, a significant increase in 
protein amounts was found in mucosa of patients with IBD. 
 Conclusion: Reduced expression of subunits of the UPS in 
IMACs of normal mucosa supports the concept of the pres-
ence of a nonreactive, anergic macrophage phenotype in the 
gut under normal conditions. Reinduction in IMACs of IBD 
mucosa reflects activated IMACs which can present antigen-
ic peptides and thus support inflammation. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The ubiquitin-proteasome system (UPS) represents 
the most important intracellular machinery for proteoly-
sis and protein degradation  [1–4] . Proteins destined for 
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 Abstract 
 Background: In normal mucosa, intestinal lamina propria 
macrophages (IMACs) maintain tolerance against food anti-
gens and the commensal bacterial flora. Several mechanisms 
have been identified that mediate tolerance. The ubiquitin-
proteasome system (UPS) is a large multiprotein complex 
that degrades cellular proteins. As the UPS may modulate im-
mune functions of IMACs, we performed a detailed investiga-
tion of UPS expression and function under normal conditions 
and in cells derived from patients suffering from inflamma-
tory bowel disease (IBD). Methods: IMACs were isolated from 
intestinal mucosa. mRNA expression of macrophages differ-
entiated in vitro (i.v. MACs) and IMACs was compared by Af-
fymetrix  oligonucleotide arrays. Quantitative Taqman-PCR 
was performed on five exemplary proteasomal and five ubiq-
uitinylation genes each. Proteins were analyzed by immuno-
histochemistry and Western blotting. Proteasome function 
was assessed by a fluorimetric test.  Results: Affymetrix anal-
ysis showed downregulation of mRNA expression of almost 
all represented proteasomal and of 22 ubiquitination-associ-
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degradation are marked by polyubiquitination and di-
gested by the proteasome  [2–4] . Ubiquitin, a compact 
globular protein of 76 amino acids, is bound to cellular 
proteins that are going to be degraded.
 Ubiquitin is activated by ‘ubiquitin-activating en-
zyme’ E1 in the presence of ATP, subsequently leading to 
the formation of ubiquitin-E1 thioester. The ubiquitin-E1 
thioester is recognized by ‘ubiquitin-conjugating en-
zymes’ E2 and ubiquitin is transferred to E2 by a further 
thioester bond. For ubiquitinylation, binding to the E2-
ubiquitin complex and direct transfer of ubiquitin to the 
target protein are required. The ‘conventional’ enzymes 
E1, E2 and E3 add only a limited number of ubiquitin 
molecules to the substrate protein. As polyubiquitinyl-
ation is necessary for the degradation signal, E4 enzymes 
support the formation of multiubiquitin conjugates.
 Before degradation of the desired protein in the pro-
teasome, ubiquitin will be released from the labeled pro-
tein. The classical deubiquitinylation enzymes are mem-
bers of the families of ubiquitin-processing enzymes 
(UBPs) and the ubiquitin carboxy terminal hydrolases 
(UBH). Normally, UBPs remove ubiquitin from poly-
ubiquitinated proteins. UBHs remove small adducts 
from ubiquitin and form free monomeric ubiquitin.
 The 26S proteasome degrades ubiquitinated proteins 
and mediates 70–90% of intracellular protein degrada-
tion  [1, 4] . It is mainly located in the cytosol. It consists of 
the 20S proteasome and two 19S caps (19S regulator). The 
20S proteasome is formed by four stapled heptametrical 
rings (  1–7,   1–7,   1–7,   1–7)  [5, 6] . The proteolytic activ-
ity is found in the inner tube to prevent unspecific degra-
dation of cytosolic proteins.
 Besides this constitutive proteasome, a conditional 
proteasome can be found in humans: the immunoprotea-
some is mainly induced by microbial infections and/or by 
IFN-   [7–11] . In addition to IFN-  , IFN-  and TNF-  
induce the expression of the three immunoproteasome 
subunits   1i (LMP2),   5i (LMP7) and   2i (MECL-1), 
which substitute for the   1,   5 and   2 subunits of the 
proteasome  [10, 12] . In mice with a deletion of   1i and 
  5i, reduced expression of MHC class I molecules and 
reduced numbers of CD8+ T cells were found  [13–15] .
 MHC class I molecules present peptides to CD8+ T 
cells. To make this possible, microbial protein must be de-
graded by the UPS. Inhibition of the UPS is followed by 
impaired function of MHC class I molecules. The UPS, 
therefore, has a central function for the induction of an 
adaptive immune response by antigen-presenting cells.
 A targeted pharmacological inhibition of the protea-
some system has been discussed in a number of diseases 
 [16–21] . However, before specifically targeting the whole 
proteasome or only specific (immuneoproteasome) com-
ponents, such as   5i/LMP7 or   2i/MECL-1, it is necessary 
to investigate its normal tissue expression and function.
 What role does the UPS play in intestinal inflamma-
tion? The UPS has been shown to degrade I  B, the in-
hibitory protein for the proinflammatory transcription 
factor nuclear factor-  B (NF-  B). If there is very low pro-
teasome activity, I  B cannot be degraded and NF-  B 
cannot be activated. In contrast, rapid I  B degradation 
by the proteasome or immunoproteasome may trigger a 
proinflammatory cascade. In addition, antigen presenta-
tion is a prerequisite for T cell activation found in the 
mucosa of patients with inflammatory bowel disease 
(IBD). A downregulation or lack of the UPS will reduce 
the number of available antigens (e.g. derived from bac-
teria) that can be presented.
 In a gene array expression study of macrophages dif-
ferentiated in vitro (i.v. MACs) and intestinal lamina pro-
pria macrophages (IMACs) we found downregulation of 
mRNA expression of  virtually all proteasome subunits in 
IMACs as compared to i.v. MACs and monocytes. Very 
similar findings were obtained for proteins of the E1, E2 
and E3 groups. This was in line with earlier findings in-
dicating that IMACs from normal mucosa are an anergic 
cell population mediating tolerance against food antigens 
and the commensal bacterial flora.
 We therefore investigated the expression and function 
of proteins of the ubiquitinylation machinery and the 
proteasomal degradation machinery during the differen-
tiation of IMACs. We focused on several genes and pro-
teins exemplary for the other genes found to be regulated 
in the array analysis.
 Materials and Methods 
 Patients 
 For Affymetrix  arrays, mRNA from isolated IMACs was 
pooled from three mucosa specimens each (6 ‘controls’ in total) 
and 3 samples of i.v. MACs (6 in total). Additional tissue samples 
were obtained from intestinal mucosa of 18 patients with Crohn’s 
disease (CD), 10 patients with ulcerative colitis (UC), 22 controls 
with no intestinal inflammation, who underwent surgery for oth-
er reasons (e.g. colon cancer) and 5 ‘inflammatory controls’ with 
diverticulitis. For more details, see online supplementary table 1 
(see www.karger.com/doi/ 10.1159/000336353 for all online suppl. 
material). The study was approved by the University of Regens-
burg Ethics Committee.
 Isolation and Purification of IMACs 
 Surgical specimens from inflamed and normal mucosa were 
obtained by surgery (online suppl. table 1) after obtaining informed 
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consent. Control specimens were taken from patients who under-
went surgery for other reasons (online suppl. table 1). Lamina pro-
pria mononuclear cells were isolated as published  [22] . IMACs were 
labeled with anti-CD33 immunomagnetic MicroBeads and puri-
fied twice using type LS separation columns (Mil tenyi Biotec, Ber-
gisch Gladbach, Germany)  [22] . The purity of the isolated macro-
phage populations was analyzed by flow cytometry after uncou-
pling of the anti-CD33 beads. Staining of the positive fraction 
demonstrated  1 90% purity of the isolated cells as described  [22] . If 
purity was less, the cells were not used for further experiments.
 Generation of i.v. MACs 
 Peripheral blood mononuclear cells were separated by leuka-
pheresis of healthy donors. Monocytes were isolated by counter-
current centrifugal elutriation in a J6M-E Beckmann centrifuge 
with a standard chamber and a JE-5 rotor at 2,500 rpm and a flow 
rate of 20 ml/min  [22] . To induce monocyte to macrophage dif-
ferentiation, purified monocytes were cultured in RPMI-1640 
supplemented with 5  ! 10 –5  M mercaptoethanol, polyvitamins, 
antibiotics, pyruvate, nonessential amino acids and 2% human 
AB group serum (endotoxin  ! 0.1 EU/ml as measured in the Lim-
ulus assay) on Teflon foils at 10 6  cells/ml (Biofolie 25, Heraeus, 
Hanau, Germany) for 7 or 14 days.
 Affymetrix Oligonucleotide Array Analysis 
 Affymetrix GeneChip  analysis was performed with the help 
of the Kompetenzzentrum für fluoreszente Bioanalytik (KFB) in 
Regensburg. mRNA was isolated from IMACs from noninflamed 
mucosa and from i.v. MACs using polyT magnetic beads (Dynal, 
Oslo, Norway). In each case, RNA from 3 patients was pooled to 
avoid individual differences responsible for variation.
 Double-stranded cDNA was synthesized by a Superscript II kit 
(Life Technologies, Karlsruhe, Germany) using T7-oligo(dT) as 
primer. Biotin-labeled cRNA was prepared by in vitro transcrip-
tion reaction using an Enzo BioArray HighYield RNA Transcript 
Labeling Kit (Affymetrix, P/N 900182). The biotin-labeled cRNA 
was purified, fragmented and after addition of Control Oligonu-
cleotide B2 (3 n M ) and 20 ! Eukaryotic Hybridization Controls 
(bioB, bioC, bioD, cre) hybridized to Affymetrix HG-U133A 
GeneChips (Affymetrix, Santa Clara, Calif., USA), scanned on 
the Affymetrix array scanner and data analysis was performed 
using the Affymetrix statistical data analysis software, Affy-
metrix Microarray Suite (version 5.0).
 Antibodies 
 The antibodies used in this work are summarized in online 
supplementary table 2. For the immunohistochemical identifica-
tion of IMACs, mouse antihuman macrophage CD68 (clone KP1, 
DAKO, Hamburg, Germany) was applied. For immunofluores-
cence, an Alexa Fluor  488 F(ab  ) 2 fragment of goat antimouse 
IgG (H + L) (Invitrogen, Karlsruhe, Germany) was used.
 Western Blotting 
 After SDS-PAGE, the proteins were transferred to a nitrocel-
lulose membrane (Optitran BA-S 83, Schleicher & Schuell). Trans-
fer was performed in a semi-dry manner (Biometra Fastblott B44, 
Biometra, Göttingen, Germany) with 1.5 mA/cm 2 for 1.5 h. The 
membrane was incubated in 5% low-fat milk in PBS (blocking so-
lution) for 1 h at room temperature. Incubation was performed at 
4   °   C overnight. On the next day, the membrane was incubated 
three times for 10 min in PBS/0.2% Tween 100 (washing buffer) 
and the HRP-conjugated secondary antibody (antirabbit, Amer-
sham) was added at a dilution of 1: 2,000 in blocking solution for 
1 h at room temperature. After washing, detection with enhanced 
chemiluminescence (ECL) followed.
 Immunohistochemistry 
 For peroxidase staining, frozen sections were cut (5   m), air 
dried and fixed in acetone. Slides were rehydrated with PBS (pH 
7.4) and incubated for 30 min with 0.3% H 2 O 2 in PBS to quench 
endogenous peroxidase. Slides were washed with PBS and incu-
bated for 60 min with 1% bovine serum albumin (Biomol, Ham-
burg, Germany) in PBS (blocking buffer) with goat serum (dilu-
tion 1: 200, Dako, Denmark).
 Microscopy was done with a Leitz DMRXE microscope with 
400 ~ magnification. Information about the magnification is 
given in the figure legends.
 Real-Time PCR (Taqman    ) 
 The primers used for quantitative PCR are given in online sup-
plementary table 3.
 A melting temperature of 60   °   C was chosen and the internal 
primers were labeled with 5  -FAM and 3  -TAMRA. DNA frag-
ments of the 5 ubiquitinylation enzymes UBE2A, UBE2D2, 
UBE2L6, USP14 und UBB and the proteasome subunits ATPase 
2,   2,   5,   2i and   5i were amplified with the respective primers. 
The reporter dye for the investigated mRNA was 6-Fam; for the 
housekeeping gene GAPDH, VIC for quenching TAMRA (6-car-
boxy-tetramethyl-rhodamine) was used. The primers were de-
signed by Primer Express 1.5 Software (PE Applied Biosystems, 
Forster City, Calif., USA) and synthesized by MWG Biotech 
(Ebersberg, Germany). The primers for GAPDH and the Taq-
man-Master Mix were from PE Applied Biosystems. Reactions 
were carried out in a volume of 20   l in triplicates. A dilution se-
ries was prepared for each primer set. Values were plotted and the 
slope of the graph was determined. The efficiency of the reaction 
was determined by calculating E = 10 –1/Slope . The error was deter-
mined by calculating (2 n /E n – 1)  ! 100 with n = Ct and given in 
percent.
 Proteasome Function 
 Proteasome activity was quantified with the Proteasome Ac-
tivity Assay Kit (Chemicon  , Nurnberg, Germany) in biopsies 
form healthy and inflamed mucosa as indicated by the manufac-
turer. The test is based on the detection of the fluorophor 7-ami-
no-4-methylcoumarin (AMC) after proteasomal cleavage from 
LLVY-AMC as a substrate and quantified in a fluorimeter at 
380/460-nm wavelengths. For assay quantification, the AMC 
standard was used. For the AMC standard curve, a stepwise dilu-
tion with concentrations from 0.04 to 12.5   M was performed. In 
addition, a positive control curve with the provided positive con-
trol was included in the assay with a stepwise dilution of the mas-
ter solution with assay buffer from 1: 4 to 1: 256. The 96-well plate 
was incubated for 1–2 h.
 Statistical Analysis 
 Data are expressed as means  8 standard deviation if not oth-
erwise stated. Statistical differences were evaluated using an un-
paired Student’s t test. p  ! 0.05 was considered statistically sig-
nificant. All statistical testing was performed using SigmaPlot  . 
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 Results 
 Affymetrix GeneChip Analysis 
 For Affymetrix GeneChip analysis, mRNA from 3 
controls and 3 i.v. MAC donors was pooled and hybrid-
ized onto two chips. Affymetrix analysis showed a sig-
nificant downregulation of virtually all proteasomal 
components as well as the ubiquitinylation machinery in 
IMACs (online suppl. tables 4 and 5).
 There were 46 probe sets for proteasome subunits rep-
resenting 35 different genes. For all probe sets, a higher 
expression in i.v. MACs as compared to IMACs was ob-
served. The ratio signal i.v. MACs /signal IMACs was between 
1.6 and 13.6 with an average of 4.3. Different probe sets 
for the same mRNA gave similar results (online suppl. 
table 4). This pointed to a lower mRNA expression of all 
proteasomal components in IMACs from normal muco-
sa as compared with i.v. MACs.
 Similar observations were made for mRNA expression 
of genes of the ubiquitinylation machinery (online suppl. 
table 5): Out of 64 probe sets representing 42 genes, the 
majority had clearly a higher signal in i.v. MACs. This was 
not observed only for ubiquitins B and C, which showed 
a high signal in both i.v. MACs and IMACs. Ubiquitin D, 
ubiquitin carrier protein and some other probe sets 
showed very low signals, making the results unreliable. In 
general, mRNA of the proteasome and the ubiquitinyl-
ation machinery showed reduced expression in IMACs 
as compared to i.v. MACs.
 To confirm these results by quantitative PCR, we chose 
five genes each. ATPase 2 was selected as it is an impor-
tant functional component. The   2- and   5- as well as 
  2i- and   5i-subunits were chosen as they are exchanged 
against each other in the immunoproteasome. The spe-
cific results for all probe sets of the genes further ana-
lyzed are shown in  figure 1 . Ubiquitin B was further ana-
lyzed as it seemed to be regulated differently and highly 
expressed as well.
 Quantification of mRNA Expression of Proteasome 
and Ubiquitination Genes in IMACs and i.v. MACs 
 ATPase2 expression was not found to be significantly 
higher in i.v. MACs as compared to IMACs ( fig. 2 a). For 
all four proteosomal subunits (  2,   5,   2i/MECL-1 and 
  5i/LMP7) we found higher expression in i.v. MACs as 
compared to IMACs from control mucosa ( fig. 2 a), thus 
confirming the array results.
 Similar results were obtained for the ubiquitination-
associated genes. However, a significant difference in 
mRNA expression between i.v. MACs and IMACs was 
only observed for UBE2A, UBE2D2, and surprisingly 
UBB (which was different to the gene chip analysis) 
( fig. 2 b). No difference was observed for mRNA expres-
sion of UBE2L6 and USP14 ( fig. 2 b).
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 Fig. 1. Results of the Affymetrix genechip arrays in four selected proteasomal subunit genes ( a ) and four se-
lected ubiquitinylation genes ( b ).  * p  ! 0.05. For some mRNAs, only one probe set revealed a significant differ-
ence. Of note: the relation of UBB expression between IMACs and i.v. MACs was inverted as compared to all 
other genes. 
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 Fig. 2. Quantification of mRNA expression of five selected pro-
teasomal subunit genes ( a ) and five selected ubiquitinylation 
genes ( b ) in IMACs and i.v. MACs. mRNA expression of the re-
spective genes was determined by quantitative PCR in i.v. MACs 
and IMACs.  a mRNA expression was higher in i.v. MACs in all 
investigated proteasomal subunits.  b A significant difference 
in ubiquitination genes was only found in UBE2A, UBE2D2 
and UBB. No difference was observed in mRNA expression of 
UBE2L6 and USP14. 
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 Quantification of mRNA Expression of Proteasome 
and Ubiquitination Genes in IBD and Diverticulitis 
Patients 
 mRNA expression of the respective genes was deter-
mined by quantitative PCR in IMACs isolated from pa-
tients with active and inactive CD or UC as well as diver-
ticulitis. In general, mRNA expression of the respective 
genes in IMACs from diverticulitis mucosa did not differ 
significantly from control IMACs ( fig. 3 a, b). The situa-
tion was different in IBD-derived IMACs. In general, 
IMACs isolated from active UC mucosa showed a clear 
increase in the expression of proteasomal subunits 
( fig. 3 a) which almost reached significance for ATPase2 
(p = 0.06). In contrast, no differences were found if 
IMACs were isolated from mucosa of UC patients in re-
mission. For CD, the situation was more complex. Only 
the expression of the   2 subunit was significantly in-
creased in IMACs isolated from active CD (p = 0.016, 
 fig. 3 a). For the expression of all other investigated pro-
teasomal subunits, no significant difference was found. 
In addition IMACs from CD patients in remission showed 
no alterations of mRNA expression. Interestingly, the ex-
pression of the   2 subunit was increased but not of that 
of the immunoproteasome subunits   2i/MECL-1 and 
  5i/LMP7. There was a trend towards an increased 
mRNA expression of these genes in IMACs from active 
CD as compared to IMACs from CD in remission and 
control IMACs ( fig. 3 a).
 The situation found for the ubiquitination genes 
( fig. 3 b) corresponded to the findings described above. 
No difference in mRNA expression of the respective 
genes was found for IMACs isolated from diverticulitis 
mucosa. A significantly increased mRNA expression in 
IMACs isolated from patients with active UC was found 
for UBE2D2, UBE2L6, USP14 and UBB ( fig. 3 b). No sig-
nificant difference was found for UBE2A. Again, there 
was a trend towards an increased mRNA expression of 
these genes in IMACs from active CD as compared to 
IMACs from CD in remission and control IMACs 
( fig. 3 b).
 Comparison of mRNA Expression of Proteasome 
(  2 and   5) and Immunoproteasome Subunits (  2i/
MECL1 and   5i/LMP7) in Normal and IBD Mucosa 
 As not only the comparison with control conditions 
but also the direct relation of   2 and   5 to   2i/MECL1 
and   5i/LMP7 proteasomal subunits might be relevant, 
we directly compared the mRNA expression of these pro-
teasomal subunits ( fig.  4 ). Expressions of both protea-
somal and immunoproteasomal subunits were low and 
comparable in IMACs from normal mucosa. A clear 
trend towards an upregulation of the immunoprotea-
some subunits was observed in IMACs isolated from CD 
and UC patients in remission ( fig. 4 ). In active disease, 
expression of   2 and   5 as well as   2i/MECL1 and   5i/
LMP7 was further increased ( fig. 4 ).
 Quantification of mRNA Expression of Proteasome 
and Ubiquitination Genes in Circulating Monocytes 
Isolated from IBD Patients and Controls 
 To investigate whether our findings in IMACs reflect 
a functional difference in this specific cell population or 
may simply be attributed to invading monocytes, we 
quantified the expression of the five proteasome and 
ubiquitination genes in circulating monocytes from IBD 
patients ( fig. 5 ). We further evaluated the impact of ste-
roid treatment on mRNA expression. Surprisingly, the 
findings in circulating monocytes were completely dif-
ferent as compared to IMACs but very homogeneous for 
all investigated genes. In  figure 5 , six of the ten genes are 
shown. The mRNA expression of the investigated genes 
was comparable to that of IMACs for circulating mono-
cytes from healthy controls. In contrast, the mRNA ex-
pression of all investigated genes was significantly down-
regulated in monocytes isolated from IBD patients irre-
spective of steroid treatment and disease activity ( fig. 5 ). 
The data indicate that the upregulation of proteasomal 
subunits found in IBD IMACs is not caused by a contam-
ination with infiltrating monocytes.
 Differences in Protein Amounts of Proteasome and 
Ubiquitin Subunits in Control Mucosa and IBD 
Patients 
 To investigate whether the differences found for 
mRNA expression would be translated into differences in 
protein amounts, we performed Western blots, immuno-
fluorescence and immunohistochemistry. As antibodies 
were not available for all techniques and for all investi-
gated proteins, we analyzed each protein by at least one 
of these methods. In  figure 6 a, Western blots for specific 
proteasomal subunits are shown. In addition to the ex-
pected 50-kDa band for ATPase 2 in IBD patients, an 
additional 20-kDa band was detected which was most 
prominent in UC-derived tissue. The positive control 
clearly indicated that the 50-kDa band was specific. After 
densitometry, a significant upregulation of ATPase 2 pro-
tein in IBD-derived IMACs was observed. The same was 
true for   2i/MECL (CD vs. control: p  ! 0.003; UC vs. con-
trol: p  ! 0.05) and   5i/LMP7 (CD vs. control and UC vs. 
control: p  ! 0.02 each) ( fig. 6 a). These findings confirmed 
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an upregulation of proteasomal subunits also on the pro-
tein level. Similar findings were obtained for the investi-
gated ubiquitinylation proteins ( fig. 6 b): for UBE2A, one 
distinct band was detected at 28 kDa, which was lower 
than the estimated molecular size. Densitometry re-
vealed a significant difference (IBD vs. control: p  ! 0.01). 
UBE2D2 protein was hardly detectable in controls at all 
and clearly induced in IBD ( fig. 6 b). UBE2L6 protein was 
similarly upregulated in IBD. Two bands were detected. 
The 17-kDa band corresponds to the expected protein 
size. The 45-kDa band could reflect a trimer or a complex 
with another protein as it showed parallel differences to 
the 17-kDa band. The differences versus control were sig-
nificant for both the 17-kDa band (p  ! 0.01) and the 45-
kDa band (p  ! 0.04). As we found no antibody for West-
ern blot detection of USP14, we next investigated UBB. 
Again, there was a significant increase of UBB (densi-
tometry: p  ! 0.005). For all performed Western blots, the 
diverticulitis protein isolated showed results similar to 
controls.
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 Fig. 3. Quantification of mRNA expressionin five selected pro-
teasomal subunit genes ( a ) and five selected ubiquitinylation 
genes ( b ) in IMACs isolated from control mucosa, CD in remis-
sion, active CD, UC in remission, active UC and diverticulitis mu-
cosa. In general, mRNA expression in IMACs isolated from di-
verticulitis patients was not different from IMACs from normal 
mucosa. The same was true for IMACs isolated from patients with 
CD and UC in remission. In patients with active CD, there was 
increased expression, which was significantly higher in active 
UC. Obviously, not only immunoproteasome subunit expression 
was increased under the mentioned conditions. 
 Fig. 4. Quantification of mRNA expression of proteasome (  2 
and   5) and immunoproteasome subunits (  2i/MECL1 and   5i/
LMP7) in normal and IBD mucosa.  a Comparison of   2 and   2i/
MECL1 mRNA expression in IMACs isolated from normal mu-
cosa, CD in remission, active CD, UC in remission and active UC. 
 b Comparison of   5 and   5i/LMP7 mRNA expression in IMACs 
isolated from normal mucosa, CD in remission, active CD, UC in 
remission and active UC. 
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 In control specimens, no positive cells could be de-
tected in the lamina propria by immunohistochemistry 
( fig. 6 c). Cells positive for   2i/MECL and   5i/LMP7 were 
detected in the lamina propria of CD and UC specimens. 
Very similar findings were obtained for UBE2L6, USP14 
and UBB ( fig. 6 d). Again, cells staining positive for the 
respective proteins were only detected in CD and UC 
specimens. This was further confirmed by immunofluo-
rescence (online suppl. material). To ensure that the cells 
expressing ubiquitination proteins in IBD patients were 
IMACs, we applied double labeling immunofluorescence 
techniques. For UBE2L6, USP14 and UBB, very similar 
staining patterns were observed: In specimens derived 
from normal mucosa, CD68+ macrophages were easily 
detected. Only in mucosal specimens from CD and UC 
patients (but not in diverticulitis-derived tissue) was a 
green fluorescence (ubiquitinylation proteins) found that 
resulted in a yellow/orange overlay (online suppl. mate-
rial). This clearly indicated that the expression of those 
proteins was induced in IMACs by chronic but not by 
acute inflammation.
 Induction of Proteasome Function in IBD Patients 
 To study whether the observed induction of protea-
some and ubiquitinylation gene mRNA and increased 
protein was also followed by increased proteasomal func-
tion, we applied a simple fluorimetric assay ( fig. 7 ). There 
was a significant difference between control and IBD tis-
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 Fig. 5. Quantification of mRNA expression of proteasome and 
ubiquitination genes in circulating monocytes isolated from IBD 
patients and controls. The expression of the investigated mRNAs 
was comparable in IMACs from control mucosa and circulating 
monocytes from healthy blood donors. In contrast, there was a 
clear downregulation of mRNA expression in monocytes of IBD 
patients, no matter how active the disease was and independent 
of the medication. 
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sue with respect to proteasomal function ( fig. 7 ). As we 
analyzed proteasome function in protein lysates from bi-
opsies, there is no parameter directly correlating protea-
somal function to the amount of IMACs present in the 
tissue. Therefore, the evidence that proteasome and ubiq-
uitinylation function is induced in IMACs from patients 
suffering from IBD is indirect at best.
 Discussion 
 In this work, we demonstrated that the ubiquitinyl-
ation machinery and expression of proteasomal compo-
nents is downregulated in IMACs as compared to i.v. 
MACs. This indicates that proteasomal function is de-
creased in IMACs. As proteasomal function, in addition 
to being associated with the intracellular degradation of 
proteins  [23–25] , is also important for antigen processing 
leading to antigen presentation  [26] , our data further ex-
plain why IMACs are ‘anergic’ and mediate tolerance. In 
this respect, the downregulation of the whole proteasom-
al machinery may be crucial for the prevention of muco-
sal inflammation.
 This again sheds light on the specific function of 
IMACs and is in line with former reports demonstrating 
lower levels of MHC II molecules  [22, 27–29] and co-
stimulatory molecules  [22, 30–33] . It is noteworthy that 
no specific part of the ubiquitinylation machinery or 
only the immune proteasome appears to be downregu-
lated in IMACs. The reduced proteasomal activity af-
fects all aspects as reflected by the homogeneous pattern 
in the array analysis that was confirmed by all subse-
quent mRNA and protein data as well as the functional 
assay.
 In contrast, IMACs from IBD mucosa but not from 
diverticulitis mucosa showed mRNA and protein upreg-
ulation of most of the investigated components. This in-
dicates that chronic but not acute inflammation alters the 
proteasomal function of IMACs. Our data further pro-
vide evidence that this functional difference is not only 
-Actin
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 Fig. 6. Protein expression of proteins involved in proteasome 
activity and ubiquitination in IMACs.  a Protein expression of 
ATPase2,   2i/MECL and   5i/LMP was clearly higher in IMACs 
isolated from CD and UC mucosa as compared to controls.  b Pro-
tein expression of UBE2A, UBE2D2, UBE2L6 and UBB was in-
creased in IMACs derived from CD and UC mucosa as compared 
to control IMACs. 
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due to the influx of newly recruited monocytes which are 
attracted to the site of inflammation. In monocytes iso-
lated from peripheral blood of IBD patients, the expres-
sion of ubiquitinylation gene expression and the protea-
somal machinery were downregulated. Therefore, the 
differences found in the mucosa are likely to be local dif-
ferences associated with IBD-specific events. As proin-
flammatory mediators also circulate in the bloodstream, 
this additionally indicates that the upregulation of the 
proteasomal machinery is not simply an unavoidable 
consequence of the presence of those soluble proinflam-
matory mediators.
 In contrast to others  [34] , we did not find a striking 
difference in proteasome subunit composition in the in-
flamed mucosa of CD and UC patients. The induction of 
expression of the immune proteasome subunits   2i and 
  5i in IMACs from IBD mucosa was more pronounced 
as compared to   2 and   5 expression; however, the 
mRNA and protein of the latter also was increased in ac-
tive IBD. It has been speculated that a difference in com-
position of the proteasome and a shift to the expression 
pattern of the immune proteasome may be followed by 
increased NF-  B activation. Steinhoff ’s group suggested 
that increased processing of p105 and rapid degradation 
of I  B  by immunoproteasomes in CD patients may be 
responsible for the enhanced expression of inflammatory 
genes regulated by p50/c-Rel and p50/p65 heterodimers 
 [34] . In contrast, our data indicate that there is no selec-
tive induction of specific proteasome subunits but a more 
or less general induction of proteasomal function without 
major selectivity that not only induces degradation of 
p105 or I  B but also changes all proteasome-associated 
functions.
 Indeed, NF-  B activation is increased in IBD IMACs 
as our group has shown before  [35] . However, this in-
creased activation is associated with an impaired barrier 
function and NOD2 variants  [36] . It would be of interest 
to further study whether the degree of induction of pro-
teasomal functions is associated with bacterial transloca-
tion and NOD2 variants.
 Clearly, the increased presence of proteasomal pro-
teins was dependent on disease activity. Surprisingly, it 
was much less influenced by treatment. Therefore, it re-
mains unclear whether induction of proteasomal func-
tion results from chronic inflammation and the presence 
of proinflammatory mediators  [37, 38] or whether, vice 
versa, strongly increased proteasomal functions make 
patients more treatment refractory.
 As striking evidence for the involvement of the com-
mensal flora in the pathogenesis of IBD has emerged in 
recent years  [39–41] , the question arises how our find-
ings could be related to these insights in disease patho-
physiology. First, it may be speculated that downregula-
tion of the proteasomal machinery prevents antigen pre-
sentation of nutritional proteins and antigens of 
commensal bacteria  [42] . The increased expression in 
IBD mucosa is in line with findings of a broken tolerance 
to food antigens  [43] or the own commensal flora that 
has been observed during active disease  [44, 45] . In fact, 
the data of Duchmann et al.  [44, 45] are frequently mis-
interpreted as  a general intolerance against the own bac-
terial gut flora in CD patients. Those data show that in-
tolerance only occurs in active disease, which would be 
in line with increased antigen presentation during this 
disease state.
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 Fig. 6. Protein expression of proteins involved in proteasome 
activity and ubiquitination in IMACs.  c   2i/MECL and   5i/LMP 
expression in the lamina propria as demonstrated by immunohis-
tochemistry was low under noninflamed conditions. In contrast, 
in CD and UC specimens, there was highly positive immunohis-
tochemical staining in the lamina propria probably in IMACs.  d 
Similarly, protein expression of UBE2L6, USP14 and UBB was in-
creased in lamina propria cells in the specimens derived from CD 
and UC mucosa. 
 Fig. 7. Proteasomal activity assay of tissue from IBD and normal 
mucosa. A clear difference between IBD mucosa and control tis-
sue was found, indicating that proteasome and ubiquitinylation 
function might be induced in IMACs from patients suffering 
from IBD.  7 
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 As under normal, noninflamed conditions expression 
of proteasomal genes is very low, it may be speculated that 
an intestinal mucosa-specific inhibition of the protea-
some could be a treatment option for IBD patients to re-
store IMAC tolerance or treatment response if it turns out 
that refractory patients have an especially high protea-
somal activity. In contrast, our data clearly indicate that 
proteasomal inhibition as a treatment for the mainte-
nance of remission will most likely not be useful.
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